Trial NCT02663518

View at ClinicalTrials.gov 
Org. Study IDs: TTI-621-01
Secondary IDs: C4961001

Last trial update was posted on 2023-07-25

MeSH Interventions

Immunoglobulin G Nivolumab Rituximab

MeSH Conditions

Hematologic Neoplasms Neoplasms

Other Conditions

Hematologic Malignancies Solid Tumor

Stopping Reasons

Pfizer decided terminating study for administrative reasons on 22Mar2022 (stopping enrollment as of 15Apr2022). The decision wasn't due to safety concerns or requests from regulatory authorities.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID